Nemak, S. A. B. de C. V. (NMAKF)
OTCMKTS · Delayed Price · Currency is USD
0.1692
0.00 (0.00%)
At close: Jul 31, 2025
Theseus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 4,915 | 4,907 | 4,993 | 4,667 | 3,798 | 3,333 | Upgrade | |
Revenue Growth (YoY) | 0.57% | -1.74% | 7.00% | 22.87% | 13.96% | -18.74% | Upgrade |
Cost of Revenue | 4,341 | 4,326 | 4,456 | 4,162 | 3,328 | 2,932 | Upgrade |
Gross Profit | 573.67 | 580.35 | 537.07 | 504.63 | 470.75 | 401.14 | Upgrade |
Selling, General & Admin | 334.67 | 354.74 | 348.51 | 293.99 | 248.39 | 252.03 | Upgrade |
Other Operating Expenses | -20.29 | -19.11 | -3.95 | -9.93 | -12.1 | - | Upgrade |
Operating Expenses | 314.37 | 335.63 | 344.56 | 284.06 | 236.28 | 252.03 | Upgrade |
Operating Income | 259.3 | 244.72 | 192.51 | 220.57 | 234.47 | 149.11 | Upgrade |
Interest Expense | -95.68 | -108.37 | -84.91 | -55.41 | -106.79 | -82.47 | Upgrade |
Interest & Investment Income | 3.72 | 4.97 | 5.62 | 2.06 | 1.65 | 2.66 | Upgrade |
Earnings From Equity Investments | 2.95 | 2.87 | 2.49 | -0.51 | -1.02 | -1.46 | Upgrade |
Currency Exchange Gain (Loss) | -76.5 | 37.39 | -56.38 | -9.79 | -20.06 | -51.26 | Upgrade |
Other Non Operating Income (Expenses) | -38.21 | -23.81 | -37.86 | -13.95 | -1.63 | -2.36 | Upgrade |
EBT Excluding Unusual Items | 55.57 | 157.75 | 21.48 | 142.98 | 106.62 | 14.22 | Upgrade |
Gain (Loss) on Sale of Assets | 1.39 | 1.39 | 11.33 | 0.22 | 0.04 | 0.3 | Upgrade |
Asset Writedown | -103.79 | -103.79 | -31.57 | -36.12 | -6.93 | -6.68 | Upgrade |
Other Unusual Items | - | - | - | - | - | -45.63 | Upgrade |
Pretax Income | -46.83 | 55.35 | 1.24 | 107.09 | 99.73 | -37.79 | Upgrade |
Income Tax Expense | 38.73 | 30.3 | -3.13 | 56.5 | 94.45 | 9.1 | Upgrade |
Earnings From Continuing Operations | -85.57 | 25.05 | 4.37 | 50.59 | 5.28 | -46.89 | Upgrade |
Net Income | -85.57 | 25.05 | 4.37 | 50.59 | 5.28 | -46.89 | Upgrade |
Net Income to Common | -85.57 | 25.05 | 4.37 | 50.59 | 5.28 | -46.89 | Upgrade |
Net Income Growth | - | 472.81% | -91.36% | 858.53% | - | - | Upgrade |
Shares Outstanding (Basic) | 2,922 | 2,941 | 3,038 | 3,055 | 3,055 | 3,077 | Upgrade |
Shares Outstanding (Diluted) | 2,922 | 2,941 | 3,038 | 3,055 | 3,055 | 3,077 | Upgrade |
Shares Change (YoY) | -1.89% | -3.19% | -0.56% | -0.02% | -0.70% | - | Upgrade |
EPS (Basic) | -0.03 | 0.01 | 0.00 | 0.02 | 0.00 | -0.02 | Upgrade |
EPS (Diluted) | -0.03 | 0.01 | 0.00 | 0.02 | 0.00 | -0.02 | Upgrade |
EPS Growth | - | 491.87% | -91.31% | 858.95% | - | - | Upgrade |
Free Cash Flow | 387.56 | 120.83 | -109.63 | 172.26 | 95.86 | 209.26 | Upgrade |
Free Cash Flow Per Share | 0.13 | 0.04 | -0.04 | 0.06 | 0.03 | 0.07 | Upgrade |
Dividend Per Share | - | - | - | - | - | 0.040 | Upgrade |
Dividend Growth | - | - | - | - | - | 648.81% | Upgrade |
Gross Margin | 11.67% | 11.83% | 10.76% | 10.81% | 12.39% | 12.04% | Upgrade |
Operating Margin | 5.28% | 4.99% | 3.85% | 4.73% | 6.17% | 4.47% | Upgrade |
Profit Margin | -1.74% | 0.51% | 0.09% | 1.08% | 0.14% | -1.41% | Upgrade |
Free Cash Flow Margin | 7.89% | 2.46% | -2.20% | 3.69% | 2.52% | 6.28% | Upgrade |
EBITDA | 560.27 | 533.96 | 465.76 | 464.98 | 489.04 | 416.42 | Upgrade |
EBITDA Margin | 11.40% | 10.88% | 9.33% | 9.96% | 12.88% | 12.49% | Upgrade |
D&A For EBITDA | 300.97 | 289.24 | 273.25 | 244.41 | 254.57 | 267.31 | Upgrade |
EBIT | 259.3 | 244.72 | 192.51 | 220.57 | 234.47 | 149.11 | Upgrade |
EBIT Margin | 5.28% | 4.99% | 3.85% | 4.73% | 6.17% | 4.47% | Upgrade |
Effective Tax Rate | - | 54.74% | - | 52.76% | 94.71% | - | Upgrade |
Advertising Expenses | - | 0.53 | 0.78 | 0.59 | 0.68 | 0.45 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.